Kannan R R Rengasamy, PhD is an expert in Nutrition at North-West University (South Africa). Kannan R R Rengasamy has authored 166 publications, the most recent in 2026. SLR score: 536 (community average: 125). How the SLR is computed.

LeadR Profile

Kannan R R Rengasamy, PhD North-West University South Africa
536 ScienceLeadR Reputation 536
Network Map

Nutrition

Subspecialties: Biochemistry - Infectiology - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2012 - 2026

Source: PubMed

Saveetha Dental College and Hospitals

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 166

Citations

Citations: 9 781 1st author: 12 Last author: 47 Unique author: 2


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Retraction notice to "Molecular targets for the management of cancer using Curcuma longa Linn. phytoconstituents: A Review" [Biomedicine & Pharmacotherapy 135 (2021) 111078].
PMID 42203602 — neoplasms, drug therapy, research
Biomed Pharmacother20260
Structure-Based Screening of Deep-Sea Microbial Metabolites Against Plasmodium falciparum Dihydroorotate Dehydrogenase.
PMID 41823820 — malaria, oxidoreductases, pharmaceutical preparations, antimalarials
Biology (Basel)20260
Deep learning-guided discovery of selective JAK2-JH2 allosteric inhibitors: integration of MLP predictive modeling, BREED-based library design, and computational validation.
PMID 41404389 — deep learning, learning, molecular dynamics simulation
Front Chem20250
The role of beta-lactamase inhibitors in combating antibiotic resistance: a historical and contemporary analysis.
PMID 41260543 — alkaloids, piperacillin, tazobactam drug combination, beta-lactamase inhibitors, enzymes, beta-lactams, research, beta-lactamases, bacteria, infections, lactams
Microb Pathog20250
In Silico Network Pharmacology, Molecular Docking, and Molecular Dynamics Analysis of Rosemary-Derived Compounds as Potential HSP90 Inhibitors for Cancer Therapy.
PMID 41150809 — pharmaceutical preparations, neoplasms, pharmacology, therapeutics
Curr Issues Mol Biol20250

LeadR Networks

Main global connection map